Currently, immunosuppressive therapies for COVID-19 are at various stages of development, including corticosteroid trials, cytokine (IL-6/1) and tocilizumab (151, 152), granulocyte-macrophage colony-stimulating factor-targeted therapies (153), Janus kinase inhibitors (154), cell adsorbents, and combined antimalarial and antibiotic therapies (e.g., hydroxychloroquine and azithromycin) (155). Here, IL6 is linked to COVID-19.